Novo Nordisk shares fall on latest trial results for new obesity drug

ResidentialBusiness · 2025-03-10T15:56:03+0000

Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema View the full article

By ResidentialBusiness
Monday at 03:56 PM in Managing Contracts and Invoices

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

Only 75 emoji are allowed.

× Your link has been automatically embedded. Display as a link instead

× Your previous content has been restored. Clear editor

× You cannot paste images directly. Upload or insert images from URL.